Amgen Inc. $AMGN Shares Sold by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd reduced its position in Amgen Inc. (NASDAQ:AMGN) by 10.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,734 shares of the medical research company’s stock after selling 4,234 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Amgen were worth $10,643,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. West Family Investments Inc. grew its holdings in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after buying an additional 30 shares in the last quarter. Viawealth LLC lifted its stake in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after buying an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its stake in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after buying an additional 30 shares in the last quarter. TAGStone Capital Inc. boosted its position in Amgen by 0.8% during the third quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after acquiring an additional 32 shares during the last quarter. Finally, BBR Partners LLC boosted its position in Amgen by 0.5% during the third quarter. BBR Partners LLC now owns 7,117 shares of the medical research company’s stock worth $2,008,000 after acquiring an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen will add medicines to the TrumpRx prescription site, which could expand patient access and volume for listed products if uptake follows; this is a near-term distribution win. GSK and Amgen to add medicines to TrumpRx, Fox Business reports
• Positive Sentiment: Product momentum — coverage highlights MariTide and osteoporosis treatments as sales drivers that have helped fuel recent rallies, supporting revenue growth expectations. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Institutional demand: Amgen is a notable holding in income-oriented funds, which supports steady shareholder demand given its long dividend track record. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Operational tie-ins: Rapid Micro Biosystems notes Amgen’s expansion of its Growth Direct system rollout — a small but constructive signal of ongoing manufacturing/capacity investments. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Neutral Sentiment: Analyst action: Jefferies issued a Hold on AMGN, a neutral rating that can dampen upside momentum vs. more bullish calls. Amgen (NASDAQ:AMGN) Earns Hold Rating from Analysts at Jefferies Financial Group
• Neutral Sentiment: Press roundups: Amgen appears in broader mega-cap watchlists and industry write-ups — visibility is high but these pieces are more contextual than catalytic. 2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds
• Negative Sentiment: Dividend/valuation concerns: Independent analysis flags high debt levels, weaker risk-adjusted returns and questions around dividend attractiveness at current prices — these are potential longer‑term headwinds for the stock’s re-rating. Dividend Stock Analysis – Amgen, Inc.

Analysts Set New Price Targets

AMGN has been the subject of a number of analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. HSBC restated a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. UBS Group boosted their price target on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Truist Financial raised their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $354.00.

Amgen Trading Down 0.4%

Shares of AMGN stock opened at $366.21 on Friday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The firm has a market cap of $197.41 billion, a PE ratio of 25.74, a price-to-earnings-growth ratio of 3.65 and a beta of 0.45. The company has a 50-day moving average of $357.73 and a two-hundred day moving average of $325.17. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.